Use Of Itolizumab On Moderate To Severe COVID-19 Patients

Biotech major Biocon has announced that it is launching a new biological drug Itolizumab to treat moderate to severe cases of COVID-19. The company received approval from the Drug Controllers General of India to market the injection for emergency use in India for treatment of cytokine release syndrome in moderate/severe cases of ARDS caused due to coronavirus.